The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Paroxetine Treatment of Generalized Anxiety Disorder: A Double-Blind, Placebo-Controlled Study
Abstract
OBJECTIVE: This study assessed the efficacy of two fixed doses of paroxetine in the treatment of generalized anxiety disorder. METHOD: Outpatients (N=566) with generalized anxiety disorder and no other axis I disorder were eligible if they scored >/=20 on the Hamilton Rating Scale for Anxiety (with a score of 2 or higher on the anxious mood and tension items). Following a 1-week placebo run-in phase, patients were randomly assigned to 8 weeks of treatment with paroxetine, 20 or 40 mg/day, or placebo. The primary outcome measure was the change from baseline in total score on the Hamilton anxiety scale. Response was defined as a rating of "very much improved" or "much improved" on the Clinical Global Impression global improvement measure; remission was defined as a Hamilton anxiety scale score </=7. Change in functional impairment was measured with the Sheehan Disability Scale. RESULTS: At 8 weeks, reductions in total score on the Hamilton anxiety scale were significantly greater for both paroxetine groups. Response was achieved by 62% and 68% of the patients receiving 20 and 40 mg of paroxetine, respectively, compared with a 46% response rate in the placebo group. Remission was achieved by 30% and 36% of patients in the 20- and 40-mg paroxetine groups, respectively, compared with 20% given placebo. For all three domains of the Sheehan Disability Scale, significantly greater improvement was seen with paroxetine than placebo. Both doses of paroxetine were well tolerated. CONCLUSIONS: This study demonstrates that paroxetine is an efficacious and well-tolerated treatment for generalized anxiety disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Sheehan, D. V., Harnett-Sheehan, K., & Raj, B. A. (1996) · International Clinical Psychopharmacology · doi:10.1097/00004850-199606003-00015 · Cited by 1,440
Self-citationDSM-III-R Generalized Anxiety Disorder in the National Comorbidity Survey
Wittchen, H.-U. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950050015002 · Cited by 967
Sartorius, N., Üstün, T. B., Lecrubier, Y., & Wittchen, H.-U. (1996) · British Journal of Psychiatry · doi:10.1192/s0007125000298395 · Cited by 541 · cited 1×
“According to an international multicenter study sponsored by the World Health Organization, generalized anxiety disorder is, after major depression, the second most frequent psychiatric disorder in the primary care setting (2), with approximately 8% of patients suffering from this illness (3).”
Method
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“Paroxetine [546,547,553-558] 1 Other antidepressants”
BackgroundBandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Bandelow, B., Bond, A., Davidson, J. R. T., den Boer, J. A., Fineberg, N. A., Knapp, M., Scott, J., et al. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105059253 · Cited by 617
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Sheehan, K. H., & Sheehan, D. V. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3282f2b4d6 · Cited by 467
Self-citationHuman and economic burden of generalized anxiety disorder
Hoffman, D. L., Dukes, E. M., & Wittchen, H.-U. (2008) · Depression and Anxiety · doi:10.1002/da.20257 · Cited by 438
Yatham, L. N., Kennedy, S. H., O'Donovan, C., Parikh, S., MacQueen, G., McIntyre, R., Sharma, V., Silverstone, P., Alda, M., Baruch, P., et al. (2005) · Bipolar Disorders · doi:10.1111/j.1399-5618.2005.00219.x · Cited by 388
Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis
Baldwin, D., Woods, R., Lawson, R., & Taylor, D. (2011) · BMJ · doi:10.1136/bmj.d1199 · Cited by 285
Treatment of substance abusing patients with comorbid psychiatric disorders
Kelly, T. M., Daley, D. C., & Douaihy, A. B. (2012) · Addictive Behaviors · doi:10.1016/j.addbeh.2011.09.010 · Cited by 284
Rickels, K., Pollack, M. H., Feltner, D. E., Lydiard, R. B., Zimbroff, D. L., Bielski, R. J., Tobias, K., Brock, J. D., Zornberg, G. L., & Pande, A. C. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.9.1022 · Cited by 280
Self-citationIdentifying HAM‐A cutoffs for mild, moderate, and severe generalized anxiety disorder
Matza, L. S., Morlock, R., Sexton, C., Malley, K., & Feltner, D. (2010) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.323 · Cited by 269
Prognostic Value of Anxiety and Depression in Patients With Chronic Heart Failure
Jiang, W., Kuchibhatla, M., Cuffe, M. S., Christopher, E. J., Alexander, J. D., Clary, G. L., Blazing, M. A., Gaulden, L. H., Califf, R. M., Krishnan, R. R., et al. (2004) · Circulation · doi:10.1161/01.cir.0000148138.25157.f9 · Cited by 264
Andrews, G., Bell, C., Boyce, P., Gale, C., Lampe, L., Marwat, O., Rapee, R., & Wilkins, G. (2018) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867418799453 · Cited by 243
Strawn, J. R., Geracioti, L., Rajdev, N., Clemenza, K., & Levine, A. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1491966 · Cited by 214
“In a second double-blind, placebo-controlled trial, Rickels and colleagues examined the efficacy of paroxetine (20 mg or 40 mg) in adults with GAD (N = 566) over an 8-week double-blind trial and noted significantly greater improvement in HAM-A scores for both doses relative to placebo, and also found paroxetine to be…”
BackgroundComer, J. S., Blanco, C., Hasin, D. S., Liu, S.-M., Grant, B. F., Turner, J. B., & Olfson, M. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05094blu · Cited by 214
Rief, W., Nestoriuc, Y., von Lilienfeld-Toal, A., Dogan, I., Schreiber, F., Hofmann, S. G., Barsky, A. J., & Avorn, J. (2009) · Drug Safety · doi:10.2165/11316580-000000000-00000 · Cited by 202
“A total of 143 studies([14-155]) 2 including 12 742 patients (11 719 in SSRI placebo groups, 1023 in TCA placebo groups) were analysed (see figure 1).”
BackgroundCarl, E., Witcraft, S. M., Kauffman, B. Y., Gillespie, E. M., Becker, E. S., Cuijpers, P., Van Ameringen, M., Smits, J. A. J., & Powers, M. B. (2020) · Cognitive Behaviour Therapy · doi:10.1080/16506073.2018.1560358 · Cited by 151
Pharmacotherapy of anxiety disorders: A critical review
Koen, N., & Stein, D. J. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.4/nkoen · Cited by 151
Optogenetic insights on the relationship between anxiety-related behaviors and social deficits
Allsop, S. A., Vander Weele, C. M., Wichmann, R., & Tye, K. M. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00241 · Cited by 150
Anxiety disorders: a comprehensive review of pharmacotherapies
Hoffman, E. J., & Mathew, S. J. (2008) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20041 · Cited by 149
Bandelow, B., Chouinard, G., Bobes, J., Ahokas, A., Eggens, I., Liu, S., & Eriksson, H. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990423 · Cited by 142
Systematic review and meta-analysis: dose-response curve of SSRIs and SNRIs in anxiety disorders
Jakubovski, E., Johnson, J. A., Nasir, M., Müller-Vahl, K., & Bloch, M. H. (2019) · Depression and Anxiety · doi:10.1002/da.22854 · Cited by 131
Current Considerations in the Treatment of Generalized Anxiety Disorder
Katzman, M. A. (2009) · CNS Drugs · doi:10.2165/00023210-200923020-00002 · Cited by 128
Gomez, A. F., Barthel, A. L., & Hofmann, S. G. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1472767 · Cited by 125
Baldwin, D. S., Huusom, A. K. T., & Mæhlum, E. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.bp.105.012799 · Cited by 114
Roest, A. M., de Jonge, P., Williams, C. D., de Vries, Y. A., Schoevers, R. A., & Turner, E. H. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.15 · Cited by 101
Effect of short-term SSRI treatment on cognitive bias in generalised anxiety disorder
Mogg, K., Baldwin, D. S., Brodrick, P., & Bradley, B. P. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1902-y · Cited by 74
Rickels, K., Etemad, B., Khalid-Khan, S., Lohoff, F. W., Rynn, M. A., & Gallop, R. J. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.170 · Cited by 63
Self-citationHoertel, N., Le Strat, Y., Blanco, C., Lavaud, P., & Dubertret, C. (2012) · Depression and Anxiety · doi:10.1002/da.21937 · Cited by 61
Sugarman, M. A., Loree, A. M., Baltes, B. B., Grekin, E. R., & Kirsch, I. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106337 · Cited by 55
Defining Response and Remission in Anxiety Disorders: Toward an Integrated Approach
Bandelow, B. (2006) · CNS Spectrums · doi:10.1017/s1092852900025815 · Cited by 52
Meta-analysis: Risk of dry mouth with second generation antidepressants
Cappetta, K., Beyer, C., Johnson, J. A., & Bloch, M. H. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.12.012 · Cited by 49
Pollack, M. H., Endicott, J., Liebowitz, M., Russell, J., Detke, M., Spann, M., Ball, S., & Swindle, R. (2008) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2007.11.006 · Cited by 35
Benzodiazepines in anxiety disorders: Reassessment of usefulness and safety
Rickels, K., & Moeller, H. J. (2019) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2018.1500031 · Cited by 30
Self-citationSafer, D. J. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000564 · Cited by 19
Antidepressants versus placebo for generalised anxiety disorder (GAD)
Kopcalic, K., Arcaro, J., Pinto, A., Ali, S., Barbui, C., Curatoli, C., Martin, J., & Guaiana, G. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012942.pub2 · Cited by 16
Anxiety and Fear-Related Disorders: Generalized Anxiety Disorder
Rosellini, A. J., & Brown, T. A. (2024) · Tasman’s Psychiatry · doi:10.1007/978-3-030-51366-5_74 · Cited by 1
Metadata
- Authors
- Rickels, K., Zaninelli, R., McCafferty, J., Bellew, K., Iyengar, M., & Sheehan, D.
- Venue
- American Journal of Psychiatry
- Published
- 2003-04-01
- Volume
- 160
- Issue
- 4
- Pages
- 749-756
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2172185379
- Cited by
- 198
- References
- 4
- FWCI
- 20.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.